CAR-T Cell Archives - WuXi Biology

OncoWuXi Express: Efficacy of DLL3 CAR-T in SHP-77 Tumor Models

OncoWuXi Express: Evaluation of DLL3 CAR-T in SHP-77-Luc Tumor Models Introduction: OncoWuXi Express will continue to keep you informed about...

Creating a Biological Switch Using DEL Technology

In addition to identifying chemical starting points for early drug discovery processes, DNA-encoded library (DEL) technology has now expanded to...

Recent Insights into Immuno-Oncology

The efficacy of CAR-T therapy is substantially influenced by the tumor microenvironment. This is particularly evident when PD-L1 is activated...

Armoring CAR-T Therapy with PD-1 Blockade

The efficacy of CAR-T therapy is substantially influenced by the tumor microenvironment. This is particularly evident when PD-L1 is activated...

AACR 2024 Posters: Sneak Peek

AACR 2024 Sneak Peek | Your All-In-One Guide to WuXi Biology’s Latest Advances in Cancer Research The American Association for...

Pioneering Advanced Modalities in Early Drug Discovery

New modalities such as peptides, oligonucleotides, and cell and gene therapies have revolutionized healthcare industry innovation. To meet these evolving...

Control of the Antitumor Activity and Specificity of CAR T Cells via Organic Adapters Covalently...

On-target, off-tumor toxicity is a specific type of toxic side effect that limits the anticancer applicability of chimeric antigen receptor...

Discovery Newsletter November 2022

PD-1 Blockade Protein in 4th Generation Armored CAR-T Cells Enhances Cytotoxicity Effect with in vitro...

Chimeric antigen receptor (CAR)-T cells are genetically engineered T cells that express a surface receptor to recognize tumor-associated antigens (TAA)....

Knowledge Library